Protheragen Joins VentriLinks as a Founding Strategic Partner to Accelerate Early-Stage Biotech Innovation

Online Inquiry

---

At Protheragen, we are continuously seeking strategic pathways to empower the next generation of biotech breakthroughs. Today, we are proud to announce our strategic alliance with VentriLinks (www.ventrilinks.com), joining their dynamic ecosystem as a Founding Strategic Partner. Together, we share a unified mission: to accelerate early-stage drug innovation, drive venture formation, and streamline strategic commercialization.

As a global drug development incubator and a premier venture-building platform, Protheragen is dedicated to advancing first-in-class therapeutic programs. We operate at the intersection of science and capital. Through our Venture-Building model, Protheragen deploys strategic capital alongside its integrated operational resources—including project incubation, rigorous R&D and IP strategy design, and strategic partnering and licensing support—to evolve innovative scientific programs from concepts into high-value, fundable therapeutic companies.

As a Founding Strategic Partner, Protheragen will collaborate closely with VentriLinks to identify and nurture high-potential therapeutic assets that align with our strategic incubation and direct investment criteria.

This synergistic partnership bridges our venture-building engine with VentriLinks’ intelligence-driven infrastructure, creating profound mutual benefits:

• Empowering Emerging Startups: Startups within the VentriLinks ecosystem will have the unique opportunity to unlock Protheragen’s direct financial backing, deep venture-building expertise, strategic development guidance, and critical pathways to broader global capital.
• Elevating Our Portfolio: Protheragen’s existing portfolio companies will gain preferred access to the cutting-edge VentriLinks platform, further enhancing their fundraising capabilities, strategic partnering, and licensing efficiency.

Ultimately, Protheragen and VentriLinks are uniting to increase the velocity of NewCo formation, optimize the crucial alignment between innovation and commercialization, and drastically reduce friction in early-stage biotech development.

We are excited to integrate our capital and operational resources into the VentriLinks ecosystem as we continue to build a more coordinated, robust infrastructure for the future of biotech innovation.

About Protheragen

Protheragen serves as a global strategic bridge dedicated to precisely connecting innovative pharmaceutical assets with worldwide partners. Backed by over a decade of cross-border transaction expertise and a multidisciplinary team of scientific, business development, and legal professionals, the company manages 200+ partner relationships and a vault of 500+ therapeutic assets. By bridging critical information and professional gaps, Protheragen acts as a localized overseas BD extension for asset owners, while providing potential buyers with highly efficient access to premium global therapeutics.

Disclaimer: Protheragen is a strategic consulting and incubation agency, rather than a regulated investment advisor or broker-dealer.